Two independent preclinical programs reported strategies that may expand CAR T utility in solid tumors. One group engineered CAR T cells with a dual receptor knockout to blunt prostaglandin E2 immunosuppression and markedly increased anti‑tumor activity in solid tumor models. Separately, Columbia University researchers published HIT (HLA‑independent T) receptor cells that detect vanishingly low antigen density and eradicated multiple solid tumor types in animal studies. The dual-receptor approach focuses on removing inhibitory signaling pathways that blunt T cell function in the tumor microenvironment; the HIT strategy raises sensitivity to low‑abundance tumor antigens, potentially widening the pool of targetable cancers. Both efforts were validated in rigorous preclinical models reported in high‑impact journals. Translational questions remain—manufacturing, safety, off‑target recognition, and persistence—but the converging engineering strategies suggest multiple paths to overcome longstanding solid tumor barriers for cell therapy.